antiparkinson agents

Summary

Summary: Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists.

Top Publications

  1. ncbi Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease
    Paul Krack
    Department of Clinical and Biological Neurosciences, Joseph Fourier University, Grenoble, France
    N Engl J Med 349:1925-34. 2003
  2. ncbi Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment
    K Ray Chaudhuri
    National Parkinson Foundation Centre of Excellence, King s College Hospital and University Hospital Lewisham, London, UK
    Lancet Neurol 8:464-74. 2009
  3. ncbi The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease
    Paolo Barone
    Università Federico II and IDC Hermitage Capodimonte, Napoli, Italy
    Mov Disord 24:1641-9. 2009
  4. ncbi Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation
    Mahmoud M Iravani
    Neurodegenerative Disease Research Centre, Institute of Pharmaceutical Sciences, School of Biomedical Sciences, King s College, London, UK
    J Neural Transm 118:1661-90. 2011
  5. ncbi Impact of the motor complications of Parkinson's disease on the quality of life
    Stéphane Chapuis
    Service de Neurologie, Centre Hospitalier Vichy, France
    Mov Disord 20:224-30. 2005
  6. ncbi Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats
    Manolo Carta
    Neurobiology Unit, Wallenberg Neuroscience Center, Department of Experimental Medical Science, Lund University, Lund, Sweden
    Brain 130:1819-33. 2007
  7. ncbi Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life
    Holger Honig
    Department of Neurology, Central Hospital, Bremerhaven, Germany
    Mov Disord 24:1468-74. 2009
  8. ncbi A randomized trial of deep-brain stimulation for Parkinson's disease
    Gunther Deuschl
    Christian Albrechts University, Kiel, Germany
    N Engl J Med 355:896-908. 2006
  9. ncbi Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease
    M Lundblad
    Department of Physiological Sciences, Wallenberg Neuroscience Centre, Neurobiology Division, Lund University, BMC A11, S 221 84 Lund, Sweden
    Eur J Neurosci 15:120-32. 2002
  10. ncbi Beta oscillatory activity in the subthalamic nucleus and its relation to dopaminergic response in Parkinson's disease
    Moran Weinberger
    Department of Physiology, Med Sci Building 3302, 1 King s College Circle, University of Toronto, Toronto, Ontario M5S 1A8, Canada
    J Neurophysiol 96:3248-56. 2006

Research Grants

Detail Information

Publications268 found, 100 shown here

  1. ncbi Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease
    Paul Krack
    Department of Clinical and Biological Neurosciences, Joseph Fourier University, Grenoble, France
    N Engl J Med 349:1925-34. 2003
    ..Although the short-term benefits of bilateral stimulation of the subthalamic nucleus in patients with advanced Parkinson's disease have been well documented, the long-term outcomes of the procedure are unknown...
  2. ncbi Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment
    K Ray Chaudhuri
    National Parkinson Foundation Centre of Excellence, King s College Hospital and University Hospital Lewisham, London, UK
    Lancet Neurol 8:464-74. 2009
    ..This Review provides a comprehensive overview of the management of this challenging aspect of PD...
  3. ncbi The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease
    Paolo Barone
    Università Federico II and IDC Hermitage Capodimonte, Napoli, Italy
    Mov Disord 24:1641-9. 2009
    ..These findings further support a key role for NMS in the clinical frame of PD and the need to address them specifically in clinical trials using dedicated scales...
  4. ncbi Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation
    Mahmoud M Iravani
    Neurodegenerative Disease Research Centre, Institute of Pharmaceutical Sciences, School of Biomedical Sciences, King s College, London, UK
    J Neural Transm 118:1661-90. 2011
    ....
  5. ncbi Impact of the motor complications of Parkinson's disease on the quality of life
    Stéphane Chapuis
    Service de Neurologie, Centre Hospitalier Vichy, France
    Mov Disord 20:224-30. 2005
    ..Nocturnal akinesia led to a deterioration of all dimensions of the PDQ-39. Thus, motor complications and especially nocturnal akinesia and biphasic dyskinesias worsened the QL of PD patients...
  6. ncbi Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats
    Manolo Carta
    Neurobiology Unit, Wallenberg Neuroscience Center, Department of Experimental Medical Science, Lund University, Lund, Sweden
    Brain 130:1819-33. 2007
    ....
  7. ncbi Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life
    Holger Honig
    Department of Neurology, Central Hospital, Bremerhaven, Germany
    Mov Disord 24:1468-74. 2009
    ..This is the first demonstration that a levodopa-based continuous dopaminergic stimulation is beneficial for NMS and health-related quality of life in PD in addition to the reduction of motor fluctuations and dyskinesias...
  8. ncbi A randomized trial of deep-brain stimulation for Parkinson's disease
    Gunther Deuschl
    Christian Albrechts University, Kiel, Germany
    N Engl J Med 355:896-908. 2006
    ..Neurostimulation of the subthalamic nucleus reduces levodopa-related motor complications in advanced Parkinson's disease. We compared this treatment plus medication with medical management...
  9. ncbi Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease
    M Lundblad
    Department of Physiological Sciences, Wallenberg Neuroscience Centre, Neurobiology Division, Lund University, BMC A11, S 221 84 Lund, Sweden
    Eur J Neurosci 15:120-32. 2002
    ..Such deficits can be quantified using novel and relatively simple testing procedures, whereas rotometry cannot discriminate between dyskinetic and antiakinetic effects of antiparkinsonian treatments...
  10. ncbi Beta oscillatory activity in the subthalamic nucleus and its relation to dopaminergic response in Parkinson's disease
    Moran Weinberger
    Department of Physiology, Med Sci Building 3302, 1 King s College Circle, University of Toronto, Toronto, Ontario M5S 1A8, Canada
    J Neurophysiol 96:3248-56. 2006
    ..The study also suggests that LFP beta oscillatory activity is generated largely within the dorsal portion of the STN and can produce synchronous oscillatory activity of the local neuronal population...
  11. ncbi Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study
    P Del Dotto
    Department of Neuroscience, Neurology Section, University of Pisa, Via Roma 67, 56100 Pisa, Italy
    Mov Disord 16:515-20. 2001
    ..This study confirms the antidyskinetic effect of amantadine and strengthens the rationale for using antiglutamatergic drugs in the treatment of parkinsonian motor fluctuations...
  12. ncbi Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia
    Incarnation Aubert
    Centre National de la Recherche Scientifique Unite Mixte de Recherche 5541, Bordeaux Cedex, France
    Ann Neurol 57:17-26. 2005
    ..Our data suggest that levodopa-induced dyskinesia results from increased dopamine D(1) receptor-mediated transmission at the level of the direct pathway...
  13. ncbi A reassessment of risks and benefits of dopamine agonists in Parkinson's disease
    Angelo Antonini
    Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy
    Lancet Neurol 8:929-37. 2009
    ..The risks of these potentially serious adverse events must therefore be taken into account and treatment decisions should be based on considerations of risks versus benefits for individual patients...
  14. ncbi Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complications
    Karla Eggert
    Department of Neurology, Philipps University of Marburg, Marburg, Germany
    Clin Neuropharmacol 31:151-66. 2008
    ..The tolerability, efficacy, and the need for dose adjustment of levodopa infusion were followed-up prospectively. Thereby, we describe clinically relevant details for how to successfully initiate and handle this new treatment strategy...
  15. ncbi Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease
    Cory Toth
    Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta, Canada
    Ann Neurol 68:28-36. 2010
    ..We sought to examine the prevalence of PN in a population of IPD patients and a potential relationship to levodopa use and fasting methylmalonic acid (MMA) levels...
  16. ncbi Subcutaneously administered apomorphine: pharmacokinetics and metabolism
    Peter A LeWitt
    Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan, USA
    Neurology 62:S8-11. 2004
    ..The complexities of apomorphine uptake, distribution, and clearance probably contribute to its variability of clinical actions...
  17. ncbi Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial
    Werner H Poewe
    Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
    Lancet Neurol 6:513-20. 2007
    ....
  18. ncbi Deep brain stimulation for the treatment of Parkinson's disease
    Jens Volkmann
    Department of Neurology, Christian Albrechts University, Kiel, Germany
    J Clin Neurophysiol 21:6-17. 2004
    ....
  19. ncbi Contribution of pre-synaptic mechanisms to L-DOPA-induced dyskinesia
    M Carta
    Neurobiology Unit, Department of Experimental Medical Science, Lund University, BMC A11, Solvegatan 17, 22184 Lund, Sweden
    Neuroscience 198:245-51. 2011
    ....
  20. ncbi Patterns of levodopa response in Parkinson's disease: a clinico-pathological study
    P A Kempster
    Queen Square Brain Bank for Neurological Disorders and Institute of Neurology, University College, London, UK
    Brain 130:2123-8. 2007
    ..A non-linear or exponential time relationship may govern the late clinical and pathological progression of Parkinson's disease...
  21. ncbi Levodopa affects functional brain networks in Parkinsonian resting tremor
    Bettina Pollok
    Department of Neurology, Heinrich Heine University, Dusseldorf, Germany
    Mov Disord 24:91-8. 2009
    ....
  22. ncbi Clinical practice. Diagnosis and initial management of Parkinson's disease
    John G Nutt
    Department of Neurology, Oregon Health and Science University, Portland 97239, USA
    N Engl J Med 353:1021-7. 2005
  23. ncbi Serotonergic modulation of receptor occupancy in rats treated with L-DOPA after unilateral 6-OHDA lesioning
    Adjmal Nahimi
    Center of Functionally Integrative Neuroscience, Aarhus University Hospitals, Aarhus University, Denmark
    J Neurochem 120:806-17. 2012
    ....
  24. ncbi Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole
    Nir Giladi
    Movement Disorders Unit, Department of Neurology, Tel Aviv Sourasky Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    Mov Disord 22:2398-404. 2007
    ..Application-site reactions were predominantly mild or moderate in intensity. In conclusion, the rotigotine transdermal patch represents an effective and safe option for the treatment of patients with early Parkinson's disease...
  25. ncbi Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease
    Christopher Kobylecki
    Faculty of Life Sciences, University of Manchester, Manchester, United Kingdom
    Mov Disord 26:2354-63. 2011
    ..These data confirm the antidyskinetic potential of topiramate and suggest that combination with low-dose amantadine may allow better reduction of dyskinesia with no adverse motor effects...
  26. ncbi Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease
    Giovanna Levandis
    Laboratory of Functional Neurochemistry, Interdepartmental Research Center for Parkinsons s Disease CRIMP, IRCCS C Mondino, Pavia, Italy
    Neurobiol Dis 29:161-8. 2008
    ..Our data confirm the role of glutamatergic neurotransmission in the pathogenesis of dyskinesias and the potential of mGluR5 antagonists in the treatment of l-DOPA-induced dyskinesias...
  27. ncbi Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats
    Hiromasa Yamada
    Department of Anatomy, Shiga University of Medical Science Otsu, Shiga 520 2192, Japan
    Neurosci Res 59:1-7. 2007
    ..The results support the assumption that exogenously administered L-DOPA may be converted into DA within the 5-HT fibers in the ST and SNR of the PD model rats...
  28. ncbi A review of Parkinson's disease
    C A Davie
    The Royal Free Hospital NHS Trust, Hampstead, London NW3 2QG, UK
    Br Med Bull 86:109-27. 2008
    ..Parkinson's disease (PD) is one of the most common neurodegenerative disorders. Sources of data Literature search using Medline with keywords Parkinson's disease supplemented with previously published papers known to the author...
  29. pmc Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats
    Kristin B Dupre
    Behavioral Neuroscience Program, Department of Psychology, Binghamton University State University of New York at Binghamton, Binghamton, NY 13902 6000, USA
    Exp Neurol 229:288-99. 2011
    ..These findings indicate a novel anti-dyskinetic mechanism of action for 5-HT(1A)R agonists with implications for the improved treatment of Parkinson's disease...
  30. ncbi The therapeutic concept of continuous dopaminergic stimulation (CDS) in the treatment of Parkinson's disease
    Fabrizio Stocchi
    Department of Neurology, IRCCS San Raffaele Pisana, Rome, Italy
    Parkinsonism Relat Disord 15:S68-71. 2009
    ..The current challenge is to develop a long-acting formulation of levodopa that simulates the pharmacokinetic pattern seen with infusions of levodopa in attempt to provide comparable benefits with an oral levodopa treatment strategy...
  31. ncbi A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease
    M Stacy
    Division of Neurology, Duke University Medical Center, Durham, NC 27705, USA
    Neurology 70:2233-40. 2008
    ..The safety and efficacy of istradefylline, a selective adenosine A(2A) receptor antagonist, was evaluated in a 12-week, double-blind study in levodopa-treated Parkinson disease (PD) subjects with motor complications...
  32. ncbi Pathological gambling in Parkinson disease is reduced by amantadine
    Astrid Thomas
    Department of Neurology, University G D Annunzio, Chieti and Pescara, Italy
    Ann Neurol 68:400-4. 2010
    ..Amantadine might be useful to treat PG. The effect of amantadine, acting as an antiglutamatergic agent, also opens new insights into the pathogenesis of PG...
  33. ncbi Stimulation of the subthalamic nucleus compared with the globus pallidus internus in patients with Parkinson disease
    Antonella Peppe
    Istituto di Ricovero e Cura a Carattere Scientifico Fondazione Santa Lucia, Clinica Neurologica and Servizio di Neurofisiopatologia Policlinico, Universita Tor Vergata, Rome, Italy
    J Neurosurg 101:195-200. 2004
    ....
  34. ncbi Gamma activity and reactivity in human thalamic local field potentials
    Florian Kempf
    Department of Neurology, Charite University Medicine, Berlin, Germany
    Eur J Neurosci 29:943-53. 2009
    ..Subcortical oscillatory activity at approximately 70 Hz may be involved in movement and arousal...
  35. ncbi Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in PD: a randomized trial
    R A J Esselink
    Department of Neurology, Academic Medical Center, Amsterdam, The Netherlands
    Neurology 62:201-7. 2004
    ..To compare the efficacy of unilateral pallidotomy and bilateral subthalamic nucleus (STN) stimulation in patients with advanced Parkinson disease (PD) in a randomized, observer-blind, multicenter trial...
  36. ncbi Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, double-blind, non-inferiority crossover study
    Fabrizio Stocchi
    Institute of Research and Medical Care, IRCCS San Raffaele Pisana, Rome, Italy
    Curr Med Res Opin 24:2883-95. 2008
    ..This study compares once-daily ropinirole 24-h prolonged release and three-times-daily ropinirole immediate release in patients with early Parkinson's disease...
  37. ncbi Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Lancet Neurol 5:677-87. 2006
    ..The current challenge is to develop a long-acting oral formulation of levodopa that provides clinical benefits but avoids motor complications...
  38. ncbi Levodopa and the progression of Parkinson's disease
    Stanley Fahn
    Columbia University, New York, USA
    N Engl J Med 351:2498-508. 2004
    ..This study assessed the effect of levodopa on the rate of progression of Parkinson's disease...
  39. ncbi Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease
    Stephen J Kish
    Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, Toronto, ON, Canada
    Brain 131:120-31. 2008
    ....
  40. ncbi Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia
    Ana Munoz
    Department of Experimental Medical Science, Neurobiology Unit, Wallenberg Neuroscience Center, University of Lund, Lund, Sweden
    Brain 131:3380-94. 2008
    ..Our results support the importance of a clinical investigation of the effect of 5-HT(1A) and 5-HT(1B) agonists, particularly in combination, in dyskinetic l-DOPA-treated Parkinson's disease patients...
  41. ncbi Chronic L-DOPA therapy alters central serotonergic function and L-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson's disease
    Sylvia Navailles
    Universite de Bordeaux, 33076 Bordeaux Cedex, France
    Neurobiol Dis 41:585-90. 2011
    ..Changes in neurochemical pattern of L-DOPA in the brain may favour the occurrence of both motor and non-motor side effects...
  42. ncbi A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa
    O Rascol
    Clinical Investigation Center, Neuropharmacology Unit, INSERM Unité 455, University Hospital, Toulouse, France
    N Engl J Med 342:1484-91. 2000
    ..There is debate about whether the initial treatment for patients with Parkinson's disease should be levodopa or a dopamine agonist...
  43. ncbi Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease
    Flora Mela
    Basal Ganglia Pathophysiology Unit, Department of Experimental Medical Science, Lund University, Lund, Sweden
    J Neurochem 101:483-97. 2007
    ..These data demonstrate that mGluR5 antagonism produces strong anti-dyskinetic effects in an animal model of Parkinson's disease through central inhibition of the molecular and neurochemical underpinnings of l-DOPA-induced dyskinesia...
  44. ncbi Oscillatory activity in the pedunculopontine area of patients with Parkinson's disease
    Alexandros G Androulidakis
    Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, University College London, Queen Square, London, UK
    Exp Neurol 211:59-66. 2008
    ..The subcortical oscillations are coupled to cortical alpha activity and possibly allied to motor related attentional processes...
  45. ncbi Subthalamic DBS replaces levodopa in Parkinson's disease: two-year follow-up
    Francois J G Vingerhoets
    Department of Neurology, BH 13, CHUV, CH 1011 Lausanne, Switzerland
    Neurology 58:396-401. 2002
    ..Since antiparkinsonian medication has short- and long-term effects that may prevent an estimate of the maximal possible impact of STN DBS, such medication was used at the lowest possible dosage after DBS implantation...
  46. ncbi Parkinson's disease: levodopa-induced dyskinesia and signal transduction
    Emanuela Santini
    Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden
    FEBS J 275:1392-9. 2008
    ..The role of this pathological adaptation and of the consequent changes in signaling in the development and expression of LID are discussed...
  47. ncbi Cerebral atrophy in Parkinson's disease patients with visual hallucinations
    B Ramirez-Ruiz
    Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Barcelona, Spain
    Eur J Neurol 14:750-6. 2007
    ..Structural changes in these areas involved in higher visual processing may be important in understanding the VH and visual deficits in PD patients...
  48. ncbi MK801 suppresses the L-DOPA-induced increase of glutamate in striatum of hemi-Parkinson rats
    Nadine Jonkers
    Department of Pharmaceutical Chemistry and Drug Analysis, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium
    Brain Res 926:149-55. 2002
    ..The suppression of this increase by prior administration of MK801 could represent a neuroprotective effect...
  49. ncbi Compensatory cortical mechanisms in Parkinson's disease evidenced with fMRI during the performance of pre-learned sequential movements
    Rosella Mallol
    Seccion de Neurologia, Hospital General de Castellón Castelló, Spain
    Brain Res 1147:265-71. 2007
    ..We concluded that in Parkinson's disease there is a compensatory mechanism of the dopamine deficit in frontostriatal motor circuits that increases participation in the execution of motor tasks of parietal-lateral premotor circuits...
  50. ncbi Coordinated and spatial upregulation of arc in striatonigral neurons correlates with L-dopa-induced behavioral sensitization in dyskinetic rats
    Véronique Sgambato-Faure
    INSERM U318, Laboratoire de Neurosciences Précliniques, CHU Pavillon B, Grenoble, France
    J Neuropathol Exp Neurol 64:936-47. 2005
    ....
  51. ncbi Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa
    Robert A Hauser
    Parkinson s Disease and Movement Disorders Center, University of South Florida, Tampa, Florida 33606, USA
    Mov Disord 22:2409-17. 2007
    ..Early treatment decisions for individual patients depend largely on the anticipated risk of side effects and long-term complications. Both ropinirole and levodopa are viable treatment options in early PD...
  52. ncbi Persistent increase in olfactory type G-protein alpha subunit levels may underlie D1 receptor functional hypersensitivity in Parkinson disease
    Jean Christophe Corvol
    Institut National de la Santé et de la Recherche Médicale Université Pierre et Marie Curie Unité 536, Institut du Fer a Moulin, 75005 Paris, France
    J Neurosci 24:7007-14. 2004
    ..In conclusion, our results revealed in the parkinsonian putamen a prolonged elevation of Galphaolf levels that may lead to a persistent D1 receptor hypersensitivity and contribute to the genesis of long-term complications of L-dopa...
  53. ncbi Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease
    Jose A Obeso
    Department of Neurology and Neurosurgery, Clinica Universitaria and Medical School and Neuroscience Centre, CIMA, University of Navarra, Pamplona, Spain
    Mov Disord 23:S548-59. 2008
    ..This creates a scenario that substantially departs from the normal physiological state of the BG...
  54. ncbi Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease
    D Nyholm
    Department of Neuroscience, Neurology, Uppsala University Hospital, SE 75185 Uppsala, Sweden
    Neurology 64:216-23. 2005
    ..To compare daytime intraduodenal levodopa/carbidopa infusion as monotherapy with individually optimized conventional combination therapies in patients with advanced Parkinson disease (PD) for motor fluctuations and quality of life (QoL)...
  55. ncbi Dopamine depletion impairs precursor cell proliferation in Parkinson disease
    Günter U Höglinger
    INSERM U289 Hôpital de la Salpetrière, F 75651 Paris, France
    Nat Neurosci 7:726-35. 2004
    ..These observations suggest that the generation of neural precursor cells is impaired in Parkinson disease as a consequence of dopaminergic denervation...
  56. ncbi Rhythm-specific pharmacological modulation of subthalamic activity in Parkinson's disease
    A Priori
    Department of Neurological Sciences, IRCCS Ospedale Maggiore di Milano, Universita di Milano, 20122 Milan, Italy
    Exp Neurol 189:369-79. 2004
    ..Multiple rhythms are consistent with the hypothesis of multiple oscillating systems, each possibly correlating with specific aspects of human STN function and dysfunction...
  57. ncbi Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years
    Mariese A Hely
    Department of Neurology, Westmead Hospital, Westmead New South Wales, Australia
    Mov Disord 20:190-9. 2005
    ....
  58. ncbi Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions
    Christopher G Goetz
    Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois 60612, USA
    Mov Disord 23:690-9. 2008
    ..Recognition of factors that impact placebo response rates should be incorporated into individual study designs for PD clinical trials...
  59. ncbi Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease
    Robert A Hauser
    Parkinsons s Disease and Movement Disorders Center, University of South Florida, 5 Tampa General Circle, Tampa, FL 33606, USA
    Mov Disord 24:564-73. 2009
    ..This might reflect enduring benefits due to neuroprotection or effects on compensatory mechanisms in early PD...
  60. ncbi Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial
    O Rascol
    Clinical Investigation Centre, Department of Clinical Pharmacology, University Hospital, Toulouse, France
    Lancet 365:947-54. 2005
    ..This study investigated rasagiline efficacy and safety in levodopa-treated patients with Parkinson's disease and motor fluctuations...
  61. ncbi Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990
    Jay A Van Gerpen
    Department of Neurology, Ochsner Clinic, New Orleans, LA, USA
    Arch Neurol 63:205-9. 2006
    ..The threat of levodopa-induced dyskinesias often influences early treatment decisions in those with Parkinson disease...
  62. ncbi Suboptimal medication adherence in Parkinson's disease
    Katherine A Grosset
    Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom
    Mov Disord 20:1502-7. 2005
    ..In conclusion, poorer compliance is associated with younger age, depression, and more tablets per day, and one-fifth of PD patients underuse medication. Consideration of drug therapy adherence has implications in the management of PD...
  63. ncbi Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration
    Thomas Muller
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Bochum, Germany
    Arch Neurol 61:657-60. 2004
    ..Levodopa metabolism via catechol O-methyltransferase increases levels of the neurotoxin homocysteine, which induces an axonal-accentuated degeneration in sensory peripheral nerves in vitro...
  64. ncbi Pathophysiology of levodopa-induced dyskinesia: potential for new therapies
    E Bezard
    Basal Gang, Laboratoire de Neurophysiologie, CNRS UMR 5543, , , 33076 Bordeaux Cedex, France
    Nat Rev Neurosci 2:577-88. 2001
    ..Our increased understanding of levodopa-induced dyskinesia is not only valuable for improving patient care, but also in providing us with new insights into the functional organization of the basal ganglia and motor systems...
  65. ncbi Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease
    R Pahwa
    University of Kansas Medical Center, Kansas City, KS 66160, USA
    Neurology 68:1108-15. 2007
    ..To evaluate the efficacy of ropinirole 24-hour prolonged release (ropinirole 24-hour) as an adjunct to levodopa in patients with Parkinson disease (PD) and motor fluctuations...
  66. ncbi Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005)
    Peter A LeWitt
    Department of Neurology, Henry Ford Hospital, Southfield, MI 48034, USA
    Ann Neurol 63:295-302. 2008
    ..Based on new understanding of nondopaminergic pathways involved in Parkinson's disease (PD) pathophysiology, a selective adenosine A(2A) receptor antagonist, istradefylline, shows promise for the treatment of PD...
  67. ncbi PREPARED: Comparison of prolonged and immediate release ropinirole in advanced Parkinson's disease
    Fabrizio Stocchi
    Department of Neurology, Institute of Research and Medical Care, IRCCS San Raffaele Roma, Rome, Italy
    Mov Disord 26:1259-65. 2011
    ..PREPARED was a randomized, parallel-group, double-blind, multicenter study to evaluate the efficacy of adjunctive ropinirole prolonged release (PR) versus immediate release (IR) in patients with advanced Parkinson's disease (PD)...
  68. pmc Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus
    D De Gaspari
    Centro Parkinson, Istituti Clinici di Pefezionamento, 20126 Milan, Italy
    J Neurol Neurosurg Psychiatry 77:450-3. 2006
    ..The clinical condition of advanced Parkinson's disease (PD) patients is often complicated by motor fluctuations and dyskinesias which are difficult to control with available oral medications...
  69. ncbi Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD
    M Guttman
    Centre for Addiction and Mental Health, Division of Neurology, Department of Psychiatry, University of Toronto, Ontario, Canada
    Neurology 56:1559-64. 2001
    ..DAT changes could influence the response to therapy in PD...
  70. ncbi Impulse control and related disorders in Parkinson's disease
    Daniel Weintraub
    Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA
    Neurodegener Dis 11:63-71. 2013
    ..As empirically validated treatments for ICDs emerge, it will also be important to examine their efficacy and tolerability in individuals with comorbid PD...
  71. pmc L-Dihydroxyphenylalanine modulates the steady-state expression of mouse striatal tyrosine hydroxylase, aromatic L-amino acid decarboxylase, dopamine and its metabolites in an MPTP mouse model of Parkinson's disease
    Jennifer M King
    Department of Neuroscience and Pharmacology, 1005 Dr D B Todd Jr Blvd Meharry Medical College, Nashville, TN 37208, USA
    Life Sci 89:638-43. 2011
    ..In turn, exogenous L-DOPA regulates the expression and activity of AAAD as well as the synthesis of DA and its metabolites, changes that may be linked to the efficacy and side-effects of L-DOPA...
  72. ncbi Levodopa in the treatment of Parkinson's disease: current controversies
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Mov Disord 19:997-1005. 2004
    ..Clinical trials to test this hypothesis are underway. We review current evidence relating to these areas of controversy...
  73. pmc Efficacy of deep brain stimulation of the subthalamic nucleus in Parkinson's disease 4 years after surgery: double blind and open label evaluation
    M C Rodriguez-Oroz
    Department of Neurology and Neurology, Neuroscience Center, Clinica Universitaria and Medical School, Universidad de Novarra, 31008 Pamplona, Spain
    J Neurol Neurosurg Psychiatry 75:1382-5. 2004
    ..To evaluate the long term (4 years) efficacy of deep brain stimulation (DBS) of the subthalamic nucleus (STN) in advanced Parkinson's disease...
  74. ncbi Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias
    Raul de la Fuente-Fernandez
    Pacific Parkinson s Research Centre, University of British Columbia, Vancouver, BC, Canada
    Brain 127:2747-54. 2004
    ..Large levodopa-induced increases in synaptic dopamine concentration can lead to dramatic changes in receptor occupancy, which may be responsible for the emergence of peak-dose dyskinesias in Parkinson's disease...
  75. ncbi A promising new technology for Parkinson's disease
    Ronald F Pfeiffer
    Department of Neurology, University of Tennessee Health Science Center, 855 Monroe Avenue, Memphis, TN 38163, USA
    Neurology 65:S6-10. 2005
  76. ncbi Differentiating vascular parkinsonism from idiopathic Parkinson's disease: a systematic review
    Seema Kalra
    Department of Neurology, Royal Infirmary, University Hospital of North Staffordshire, Stoke on Trent, United Kingdom
    Mov Disord 25:149-56. 2010
    ..The development of accepted international diagnostic criteria for VP is urgently needed to facilitate further studies...
  77. ncbi Subacute axonal neuropathy in Parkinson's disease with cobalamin and vitamin B6 deficiency under duodopa therapy
    Peter P Urban
    Department of Neurology, Asklepios Klinik Barmbek, Hamburg, Germany
    Mov Disord 25:1748-52. 2010
    ..Comprehensive diagnostic workup including muscle and sural nerve biopsy revealed that the most probable cause of subacute axonal peripheral neuropathy was cobalamin and vitamin B6 deficiency in both the patients...
  78. ncbi Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial
    Anthony H V Schapira
    Institute of Neurology, University College London, London, UK
    Neurology 77:767-74. 2011
    ..In advanced Parkinson disease (PD), immediate-release pramipexole, taken 3 times daily, improves symptoms and quality of life. A once-daily extended-release formulation may be an effective and simple alternative therapy...
  79. ncbi Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets
    Dag Nyholm
    Department of Neuroscience, Neurology, Uppsala University, Sweden
    Clin Neuropharmacol 26:156-63. 2003
    ..Continuous intraduodenal delivery of a new carbidopa/levodopa formulation offers a means for markedly improved control of motor fluctuations in late stages of PD...
  80. ncbi Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease
    David Devos
    Department of Neurology, EA2683 IFR114 IMPRT, Hopital R Salengro, CHU Lille, France
    Mov Disord 24:993-1000. 2009
    ..Technical problems were commonplace. Duodenal levodopa infusion seems to be an effective last-line therapy for motor complications in Parkinson's disease. Hence, technical improvements and earlier introduction should be considered...
  81. ncbi Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome
    Angelo Antonini
    Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy
    Mov Disord 22:1145-9. 2007
    ..05). Two patients withdrew for adverse events. Our results demonstrate that a satisfactory therapeutic window can be achieved and maintained for several months in advanced PD patients...
  82. pmc Levodopa in the treatment of Parkinson's disease: an old drug still going strong
    Werner Poewe
    Department of Neurology, Medical University of Innsbruck, Austria
    Clin Interv Aging 5:229-38. 2010
    ..This review summarizes the available evidence regarding the use of LD to treat PD and will also address the issue of LD delivery as a critical factor for the drug's propensity to induce motor complications...
  83. ncbi Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease
    Robert A Hauser
    Parkinson s Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA
    Mov Disord 26:2246-52. 2011
    ..IPX066 provided more sustained plasma levodopa concentrations than immediate-release carbidopa-levodopa. Larger, longer-term, well-controlled studies should be conducted to provide rigorous assessment of the clinical effects of IPX066...
  84. ncbi Focusing effects of L-dopa in Parkinson's disease
    Bernard Ng
    Department of Electrical and Computer Engineering, The University of British Columbia, Vancouver, Canada
    Hum Brain Mapp 31:88-97. 2010
    ..This observation is consistent with modeling studies, which demonstrated that dopamine increases the signal-to-noise ratio at the neuronal level with a resultant focusing of representations at the macroscopic level...
  85. pmc Targets for neuroprotection in Parkinson's disease
    Talene A Yacoubian
    Department of Neurology, Center for Neurodegeneration and Experimental Therapeutics, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Biochim Biophys Acta 1792:676-87. 2009
    ....
  86. ncbi Effects of sarizotan on the corticostriatal glutamate pathways
    Tiziana Antonelli
    Department of Clinical and Experimental Medicine, Section of Pharmacology, University of Ferrara, Italy
    Synapse 58:193-9. 2005
    ....
  87. ncbi Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Nat Clin Pract Neurol 2:382-92. 2006
    ..The current challenge is to develop a long-acting oral formulation of levodopa that provides comparable anti-parkinsonian benefits without motor complications...
  88. pmc Amantadine for dyskinesias in Parkinson's disease: a randomized controlled trial
    Hideyuki Sawada
    Clinical Research Center, Utano National Hospital, Kyoto City, Japan
    PLoS ONE 5:e15298. 2010
    ..The purpose of the present study was to investigate the efficacy of amantadine in Parkinson's disease patients suffering from dyskinesias...
  89. ncbi Practical considerations in the use of apomorphine injectable
    Annette Bowron
    Jubilee Day Hospital, North Tyneside General Hospital, Tyne and Wear, United Kingdom
    Neurology 62:S32-6. 2004
    ....
  90. ncbi Neuroprotective effects of pramipexole in young and aged MPTP-treated mice
    D W Anderson
    Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, 1020 Locust Street, JAH 521, Philadelphia, PA 19107, USA
    Brain Res 905:44-53. 2001
    ..These findings support the early initiation of PPX therapy in Parkinson's disease patients...
  91. ncbi Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study
    Fabrizio Stocchi
    Institute of Neurology, IRCCS San Raffaele Pisana, Rome, Italy
    Ann Neurol 68:18-27. 2010
    ....
  92. ncbi Abnormal bidirectional plasticity-like effects in Parkinson's disease
    Ying Zu Huang
    Department of Neurology, Chang Gung Memorial Hospital, Taipei 10507, Taiwan
    Brain 134:2312-20. 2011
    ....
  93. ncbi Sustained-release formulation of levodopa methyl ester/benserazide for prolonged suppressing dyskinesia expression in 6-OHDA-leisoned rats
    Tiantian Ren
    School of Pharmacy, Shanghai Jiao Tong University, No 800 Dongchuan Road, Shanghai 200240, China
    Neurosci Lett 502:117-22. 2011
    ..These data showed that LDME/benserazide-loaded microspheres could be used to treat PD motor symptoms and ameliorate the expression of LID in this rat model of PD...
  94. ncbi Levodopa influences striatal activity but does not affect cortical hyper-activity in Parkinson's disease
    K Martinu
    Functional Neuroimaging Unit, Centre de Recherche, Institut Universitaire de Geriatrie de Montreal, 4545 Queen Mary, Montreal, QC, H3W 1W5, Canada
    Eur J Neurosci 35:572-83. 2012
    ....
  95. ncbi Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD
    F Bibbiani
    ETB, NINDS, National Institutes of Health, Bethesda, MD 20892, USA
    Exp Neurol 196:422-9. 2005
    ....
  96. ncbi N-acetyl-L-methionyl-L-Dopa-methyl ester as a dual acting drug that relieves L-Dopa-induced oxidative toxicity
    Alba Minelli
    Dipartimento Medicina Sperimentale Scienze Biochimiche, Sezione Biochimica Cellulare, Universita di Perugia, Via del Giochetto, 06124, Perugia, Italia
    Free Radic Biol Med 49:31-9. 2010
    ..Moreover, by using proteasome inhibitor-treated mice as Parkinson's disease animal model, we demonstrated the beneficial effects of the systemic administration of this novel codrug...
  97. ncbi Ten-Hertz stimulation of subthalamic nucleus deteriorates motor symptoms in Parkinson's disease
    Lars Timmermann
    Department of Neurology, Heinrich Heine University, Dusseldorf, Germany
    Mov Disord 19:1328-33. 2004
    ..This finding indicates the clinical relevance of pathological 10 Hz synchronization in PD...
  98. pmc Subthalamic deep brain stimulation at individualized frequencies for Parkinson disease
    E W Tsang
    Division of Brain Imaging and Behaviour Systems Neuroscience, Toronto Western Research Institute, University Health Network, University of Toronto, Ontario, Canada
    Neurology 78:1930-8. 2012
    ..We hypothesized that STN deep brain stimulation (DBS) at individualized γ frequencies would improve whereas θ or β frequencies would worsen PD motor signs...
  99. ncbi Drug adherence in Parkinson's disease
    Norman A Leopold
    Division of Neurology, Department of Medicine, Crozer Chester Medical Center, Upland, Pennsylvania 19013, USA
    Mov Disord 19:513-7. 2004
    ..Mistiming of doses was admitted by 73% of subjects but 82.1% had recorded mistimed doses. Of multiple sociodemographic and disease-related items examined, only gender and level of education were statistically related to nonadherence...
  100. pmc Movement-related changes in local and long-range synchronization in Parkinson's disease revealed by simultaneous magnetoencephalography and intracranial recordings
    Vladimir Litvak
    Sobell Department of Motor Neuroscience, UCL Institute of Neurology, London, WC1N 3BG, United Kingdom, Department of Clinical Neurology, University of Oxford, Oxford, OX3 9DU, United Kingdom
    J Neurosci 32:10541-53. 2012
    ..We conclude that synchronization at 60-90 Hz in the basal ganglia cortical network is prokinetic but likely through a modulatory effect rather than any involvement in explicit motor processing...

Research Grants63

  1. DRUG-INDUCED MOVEMENT DISORDERS IN SCHIZOPHRENIA
    William Hoffman; Fiscal Year: 1991
    ..Usually, neuroleptics suppress TD while antiparkinson agents enhance it. Opposite effects occur for DIP...
  2. Multiple Factors Affecting Placebo Response in PD
    Christopher Goetz; Fiscal Year: 2004
    ..Defining these determinant influences will help enhance placebo responses in clinical practice and control them in clinical trials. ..
  3. DOUBLE-BLIND CONTROLLED TRIAL OF NIGRAL GRAFTING IN PD
    C Olanow; Fiscal Year: 2003
    ..abstract_text> ..
  4. LEVODOPA PHARMACOKINETICS AND PHARMACODYNAMICS
    John Nutt; Fiscal Year: 2008
    ..unreadable] [unreadable]..
  5. Nocardia: A Novel Environmental Agent For Parkinsonism?
    Peter LeWitt; Fiscal Year: 2003
    ..These outcomes will be significant because they should add to our understanding of the neurodegenerative process in PD, and could lead to improved means of diagnosis and treatment for individuals with this disorder. ..
  6. Southeastern Michigan Parkinson's Disease Program
    Peter LeWitt; Fiscal Year: 2006
    ..This application also discusses concepts for three pharmacological agents that could be investigated in pilot studies and, if promising, in multicenter clinical trials for assessing neuroprotection. ..
  7. GM1 Ganglioside Effects on Parkinson's Disease
    Jay Schneider; Fiscal Year: 2007
    ..Working hypothesis: Long-term GM1 use will stabilize symptoms or slow the progression of symptoms in PD patients and this may be accompanied by reduced loss of striatal DA terminals over time. [unreadable] [unreadable]..
  8. Nicotine and Cognition in Parkinsonism
    Jay Schneider; Fiscal Year: 2008
    ..Information obtained from these studies will hopefully lead to more efficient design of nicotinic therapeutics for patients with a variety of cognitive disorders. ..
  9. Nicotinic Receptors in Parkinson's Disease
    Maryka Quik; Fiscal Year: 2007
    ..These data together with the results of the behavioral studies may form a basis for the use of nicotinic drugs in the treatment of Parkinson's disease. [unreadable] [unreadable]..
  10. Economic and Policy Analyses in Geriatric Disease
    EKATERINA NOYES; Fiscal Year: 2006
    ..The model and analytical approaches acquired by the candidate during her training will be used later to develop a decision analytical model describing geriatric depression. ..
  11. GENETICS OF PARKINSON DISEASE IN THE AMISH
    Brad Racette; Fiscal Year: 2006
    ..abstract_text> ..
  12. MESOLIMBIC DOPAMINE D3 RECEPTOR AND PARKINSON'S DISEASE
    Jeffrey Joyce; Fiscal Year: 2002
    ..This will further elucidate the pathology of DAergic substrates of specific clinical symptoms in PD and provide a broader basis for developing effective treatment strategies based on specific DA receptors. ..
  13. Nicotinic and neuroprotection in a parkinson mouse model
    Maryka Quik; Fiscal Year: 2007
    ..This may allow for the design of neuroprotective strategies for PD, a disorder for which only symptomatic treatment is currently available. ..
  14. Epidemilogy of Parkinsonism in Welders
    Brad A Racette; Fiscal Year: 2011
    ..The cohort assembled will provide unique opportunities for future research projects into gene-environment interactions and exposure related neuroimaging changes. ..
  15. Neural Interactions in Incremental and Episodic Memory
    Daphna Shohamy; Fiscal Year: 2006
    ..abstract_text> ..
  16. SC Cooperative for Healthy Aging in Minority Populations
    Barbara Tilley; Fiscal Year: 2006
    ....
  17. Targeting Adenosine A2A Receptors in Parkinson's Disease
    Michael Schwarzschild; Fiscal Year: 2006
    ..Thus this timely conference is designed to catalyze the development of A2A antagonists as a novel multi-faceted treatment strategy for Parkinson's disease and related CMS disorders. [unreadable] [unreadable] [unreadable]..
  18. Novel Neuroprotection by Caffeine in Parkinson's Disease
    Michael Schwarzschild; Fiscal Year: 2005
    ....
  19. Translational Foundation of Adenosine Antagonist Use for Dyskinesias
    Michael A Schwarzschild; Fiscal Year: 2010
    ....
  20. A1/A2A Receptors and Caffeine Psychostimulation
    Jiang Fan Chen; Fiscal Year: 2009
    ..abstract_text> ..
  21. Predicting Driver Safety in Parkinson's Disease
    Ergun Uc; Fiscal Year: 2007
    ..Fair and accurate means of detecting unfit drivers with PD will help mitigate the tragedy of motor vehicle crashes caused by these impaired individuals. ..
  22. Efferent Vestibular Mechanisms
    MEIR PLOTNIK PELEG; Fiscal Year: 2003
    ..The significance of this research is in setting the foundations of mammalian efferent neuron physiology, and providing experimental data on the control mechanism by which the EVS operates. ..
  23. Impulse Control Disorders in Parkinson's Disease Conference
    Mark Stacy; Fiscal Year: 2007
    ..To date, there has not been a workshop or meeting dedicated to the discussion of this evolving field. [unreadable] [unreadable] [unreadable]..
  24. DEPRESSION DIAGNOSIS AND TREATMENT IN PARKINSON DISEASE
    Daniel Weintraub; Fiscal Year: 2008
    ..abstract_text> ..
  25. Long-term Ambulatory Gait Monitor for Parkinson's Disease
    Steven Moore; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  26. Bioinformatics & identification of cis elements for dopamine gene expression
    Jiang Fan Chen; Fiscal Year: 2008
    ....
  27. Effects of Nicotine on Human Cerebral Transmitters
    EDWARD DOMINO; Fiscal Year: 2008
    ..This research will provide direct proof of basic neuroscience studies, which indicate nicotine releases neurotransmitters such as dopamine and endogenous opioids. [unreadable] [unreadable] [unreadable]..
  28. MIDCAREER INVESTIGATOR AWARD--PATIENT ORIENTED RESEARCH
    Karl Kieburtz; Fiscal Year: 2003
    ..abstract_text> ..
  29. Chinese Exercise Modalites in Parkinson's Disease
    Jorge Juncos; Fiscal Year: 2003
    ..A better understanding of exercise-induced neural plasticity and motor control would offer a significant, and heretofore unexploited rehabilitative potential in PD. ..
  30. Transcranial Magnetic Stimulation and Neuromodulation
    Jau Shin Lou; Fiscal Year: 2003
    ..The results will provide us with vital information that will allow us to further develop rTMS as a noninvasive therapeutic modality for PD. ..
  31. IMAGING MARKERS FOR ASSESSING PROGRESSION IN MOVEMENT
    Andrew Feigin; Fiscal Year: 2003
    ..The extension of this career development award will allow the candidate to become a fully independent and productive clinical scientist. ..
  32. Translating A2A Receptor Biology into Novel PD Therapy
    Michael Schwarzschild; Fiscal Year: 2002
    ..Thus, this timely conference stands to serve as a catalyst for developing A2A antagonists as a novel multi-faceted treatment strategy for Parkinson's disease. ..
  33. Sensory-enhanced motor training for hemiparetic arm/hand
    Wen Liu; Fiscal Year: 2004
    ..The effect of enhanced sensory inputs will be determined through the comparison of outcomes of the two training programs. ..
  34. ADENOSINE /DOPAMINE INTERACTIONS IN A2A RECEPTOR KO MICE
    Jiang Fan Chen; Fiscal Year: 2002
    ..abstract_text> ..
  35. fMRI Activity During the Visual Control of Force
    DAVID VAILLANCOURT; Fiscal Year: 2004
    ..These findings will have further implications for better understanding the visuomotor control deficits associated with aging, and diseased persons with Parkinson's disease, ataxia, and cerebellar deficits. ..
  36. NICOTINE EFFECTS ON CEREBRAL BLOOD FLOW AND METABOLISM
    EDWARD DOMINO; Fiscal Year: 2001
    ..This could set the stage for the study of nicotine effects in persons with cofactors for smoking, such as attention deficit disorder or mood disorders. ..
  37. A2A Adenosine Receptors in Psychostimulant Sensitization
    Michael Schwarzschild; Fiscal Year: 2005
    ..clarify the role of A2A receptors in psychostimulant-induced addictive behaviors, and thus may encourage the development of novel, specific strategies for treating psychostimulant abuse and related addiction disorders ..
  38. ROLE OF PROTEASOMAL DYSFUNCTION IN PARKINSON'S DISEASE
    KEVIN MCNAUGHT; Fiscal Year: 2008
    ..These studies will test our hypothesis that inadequate proteasomal function underlies both vulnerability and degeneration of the SNc in sporadic Parkinson's disease. ..
  39. Toxicant, oxidative injury, dopamine & synuclein in PD
    KATHLEEN ANNE MAGUIRE ZEISS; Fiscal Year: 2011
    ..The mechanistic information derived may enable new glial-oriented therapeutic initiatives. ..
  40. MOTOR EFFECTS OF ATYPICAL ANTIPSYCHOTICS
    John Salamone; Fiscal Year: 2003
    ..Taken together, the results of these experiments will help to identify the pharmacological characteristics and brain circuits that underlie the motor effects of clozapine. ..
  41. The Role of Parkin in Parkinson's Disease
    Ted Dawson; Fiscal Year: 2009
    ....
  42. Folate, DNA Methylation and Breast Tumorigenesis
    Joshua Miller; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  43. Deep brain stimulation of the ventral anterior limb of the internal capsule for m
    Andre Machado; Fiscal Year: 2009
    ..In this proposal, we describe an innovative approach to alleviate suffering and disability among those with severe and refractory chronic neuropathic pain. ..
  44. Effort-related Functions of Nucleus Accumbens Adenosine A2A Receptors
    John D Salamone; Fiscal Year: 2010
    ....
  45. A Comprehensive Database of Cost-Effectiveness Analyses
    Peter Neumann; Fiscal Year: 2003
    ..The web-based data should also understand the needs of different scientists to be understood and policymakers, and bridges to be built across disparate communities. ..
  46. Arm Kinematics in Hyperkinetic Cerebral Palsy
    Terence Sanger; Fiscal Year: 2005
    ..Hlatky will guide the design and implementation of clinical trials and outcome measure validation. The proposal includes coursework in cellular and molecular neurobiology and in the design of clinical research studies. ..
  47. Biomarkers of Aging in the Bay Area Sleep Cohort
    Donald Bliwise; Fiscal Year: 2005
    ..abstract_text> ..
  48. Models of Familial Parkinson's Disease: PINK1
    Ted Dawson; Fiscal Year: 2006
    ....
  49. Statistical Methods for Neurological Data
    Paulo Guimaraes; Fiscal Year: 2006
    ..In the last year of the award the candidate will concentrate on developing a/research agenda on the application of statistical methods to neuroimaging data. ..
  50. IMAGING PROCEDURAL+WORKING MEMORY IN PARKINSON'S DISEASE
    Daniel Press; Fiscal Year: 2006
    ..The integrated training and research program will allow the candidate to develop the tools to become an independent investigator of the cognitive deficits in Parkinson?s disease. ..
  51. Models of Familial Parkinson's Disease: DJ-1 Knockouts
    Ted Dawson; Fiscal Year: 2005
    ....
  52. PANDAS and Strep Infection: Are they Linked?
    Roger Kurlan; Fiscal Year: 2004
    ..Disproving the PANDAS hypothesis would prevent the use of expensive and potentially dangerous therapies (e.g., plasma exchange, immune globulin, antibiotics) that have been proposed for PANDAS patients. ..
  53. Creatine Therapy for Huntington's Disease
    Steven Hersch; Fiscal Year: 2004
    ..These studies are intended to provide the basis of a subsequent phase III trial of creatine in HD. ..
  54. NURR1 Gene Mutations in Parkinson's Disease
    Weidong Le; Fiscal Year: 2006
    ....
  55. Dopamine D2 and Adenosine A2A roles:Tremulous Movements
    John Salamone; Fiscal Year: 2007
    ..abstract_text> ..
  56. Functional Neuroimaging of Cognitive Dysfunction in HIV-HCV Co-Infection
    Robert Paul; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable]..
  57. HUNTINGTON PROTEIN AND THE HUNTINGTON'S DISEASE MUTATION
    Steven Hersch; Fiscal Year: 2003
    ..In Specific Aim 4, we will examine apoptosis as a mechanism of cell death in transgenic HD animals by direct examination and by crossing tem with transgenic animal lines relevant to apoptotic death. ..
  58. Reversible and Temporally Inducible LRRK2 Knockout Mice
    Ted Dawson; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  59. DITHIOCARBAMATE PESTICIDES IN PARKINSON'S DISEASE
    Jing Zhang; Fiscal Year: 2003
    ..The new information will shed more light on the mechanisms by which pesticides interact with aging and genetic vulnerability thereby contributing to development and progression of PD. ..
  60. Structure-Function Analysis of the D3 Dopamine Receptor
    Eldo Kuzhikandathil; Fiscal Year: 2003
    ..In doing so, ti study will make significant contributions toward ongoing efforts to define the role of D3 receptor neurological disorders such as schizophrenia. ..
  61. GAIT INSTABILITY IN THE ELDERLY WITH INCREASED FALL RISK
    Jeffrey Hausdorff; Fiscal Year: 2008
    ..abstract_text> ..
  62. Aberrant Synaptic Plasticity: Impact of Dopamine on Graft Outcome
    Kathy Steece Collier; Fiscal Year: 2008
    ..abstract_text> ..